1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
NAPSRx Logo

J & J's alliance with life science companies fuel research and development for Pharma/Biotech

Johnson & Johnson Innovation, LLC focuses on accelerating early-stage innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare business

 
PRLog - Jun. 27, 2014 - WASHINGTON, D.C. -- Johnson & Johnson Innovation, LLC had announced in mid-June multiple alliances with various life science companies to explore early stage innovation across various therapeutic areas.

“The future of healthcare will be defined by companies, academic institutions and governments that collaborate to leverage existing strengths, while at the same time think outside current paradigms and experiment with new ways of innovating,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Pharmaceuticals. “By being where these new frontiers in science and technology are being forged, our goal is to translate these insights into promising treatments for the future.”

According to a press release issued by Johnson & Johnson Innovation, LLC, the following collaborations will focus on specific therapeutic areas.  Some of the partnerships will notably benefit the pharmaceutical and biotech industry, these include:

1.       Targeting Lymphoma – Janssen Biotech, Inc. and Johnson & Johnson Innovation have formed a research collaboration with Weill Cornell Medical College aimed at evolving compounds to targeting the function of a lymphoma causing protein

2.       Immunotherapies for Prostate Cancer – Janssen Biotech, Inc. and Johnson & Johnson Innovation have obtained an exclusive, worldwide license from Aduro BioTech to certain product contenders for the treatment of prostate cancer.

3.       Dementia Research –The neuroscience therapeutic area of Janssen Research & Development, LLC will participate in the U.K. Dementias Research Platform (http://www.mrc.ac.uk/research/facilities/dementias-resear...).

4.       Insomnia– Janssen Pharmaceuticals N.V., the Janssen neuroscience therapeutic area will participate in research collaboration with Minerva Neurosciences, subject to certain conditions, around the development of an orexin-2 antagonist, MIN-202, focusing on patients with primary and secondary insomnia and other related neuropsychiatric disorders.

5.       Epigenetic Modulators in the CNS – Johnson & Johnson Development Corporation contributed in the Series A equity investment of Rodin Therapeutics in collaboration with Johnson & Johnson Innovation. Research and development is dedicated to locating epigenetic modulators for the treatment of cognitive disorders, including Alzheimer’s disease.

6.       Creating New Brown Fat – Janssen Pharmaceuticals, Inc. and Johnson & Johnson Innovation have established a collaboration with the biotechnology company Energesis Pharmaceuticals, to recognize biological compounds that fuel the materialization of brown fat (BAT) for use in treating metabolic diseases.

7.       Nutrient-Sensing Pathway – Johnson & Johnson Development Corporation made an  investment in Navitor Pharmaceuticals in collaboration with Johnson & Johnson Innovation.  Navitor is leveraging the central importance of the mTORC1 pathway to develop new therapies for metabolic diseases, like diabetes, as well as autoimmune, mulsculoskeletal and other disease areas.

8.       Cardiac– Johnson & Johnson Development Corporation made an equity investment in Ascelegen Therapeutics in collaboration with Johnson & Johnson Innovation. Ascelegen is working on developing growth factor related therapies for cardiovascular diseases, including heart failure.

9.       Halting Autoantigen Production in Rheumatoid Arthritis and Other Autoimmune Diseases – Johnson & Johnson Development Corporation participated in a Series A equity investment in Padlock Therapeutics in collaboration with Johnson & Johnson Innovation. The company is dedicated to develop new therapies targeting the protein arginine deiminases, a class of enzymes that facilitate protein citrullination. Protein citrullination creates potent autoantigens leading  to rheumatoid arthritis and drives inflammation and immune complex formation in active autoimmune disease.

10.     The Microbiome’s Impact on Health and Disease – Johnson & Johnson Consumer Companies, Inc. and Johnson & Johnson Innovation have collaborated with scientists from The University of Manchester to explore potential uses of probiotic extracts for prevention and treatment of skin, oral and respiratory infections.

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!

With such industry leaders paving the way in the advancement of new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio.  When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR)

Contact
NAPSRx
1-800-284-1060
***@napsronline.org

--- End ---

Click to Share

Contact Email:
***@napsronline.org Email Verified
Source:NAPSRx
City/Town:Washington - District of Columbia - United States
Industry:Biotech, Health
Tags:Pharmaceutical Innovation, biotech, cnpr training, napsrx, sales marketing
Last Updated:Jun 27, 2014
Shortcut:prlog.org/12342266
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share